Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease

Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer's Disease

This study will compare atomoxetine to placebo when taken with current standard Alzheimer's Disease medications. The treatment will take approximately 6 months and it is hypothesized atomoxetine will significantly improve cognitive performance as compared to placebo.

Inclusion Criteria:

• Patient presents with Alzheimer's Disease based on clinical history.
• Patient must have a Mini Mental Status Score between 10 and 26.
• Patient must have a reliable caregiver in frequent or daily contact with the patient.
• Patient must be currently treated with and on a stable dose of a standard Alzheimer's drug treatment for at least 3 months.

Exclusion Criteria:

• Patients who are receiving pharmacologic treatments (other than a cholinesterase inhibitor or memantine) for Alzheimer's Disease.
• Patients who have a history in the past 5 years or any current evidence of major psychiatric illness.
• Patients who have narrow angle glaucoma.
• Patients who are experiencing clinically significant urinary hesitancy or retention as assessed by a physician.